Lung Volume Reduction Therapy Using Crosslinked Non-Natural Polymers
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application 60/917,419, filed May 11, 2007. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,445,589 | Lung Volume Reduction Therapy Using Crosslinked Non-Natural Polymers In force · High confidence UsedRemaining | Pulmonx Corporation | In force | High confidence | ||
| US 9,006,340 | Lung Volume Reduction Therapy Using Crosslinked Non-Natural Polymers In force · High confidence | Pulmonx Corporation | In force | High confidence | ||
| US 9,561,301 | Lung Volume Reduction Therapy Using Crosslinked Non-Natural Polymers In force · High confidence | Pulmonx Corporation | In force | High confidence | ||
| US 9,999,701 | Lung Volume Reduction Therapy Using Crosslinked Non-Natural Polymers In force · High confidence | Pulmonx Corporation | In force | High confidence | ||
| US 8,198,365 | Lung Volume Reduction Therapy Using Crosslinked Non-Natural Polymers In force · High confidence | Pulmonx Corporation | In force | High confidence |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.